Rapamycin and Alzheimer's disease: Time for a clinical trial?

Published in: Science translational medicine (2020)

The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

Keyphrases

clinical trial
cognitive decline
phase ii
mouse model
cell proliferation
open label
randomized controlled trial
double blind
emergency department
adverse drug
cell therapy